Malignant neoplasm of overlapping sites of corpus uteri
ICD-10 C54.8 is a billable code used to indicate a diagnosis of malignant neoplasm of overlapping sites of corpus uteri.
C54.8 refers to malignant neoplasms that occur in overlapping sites of the corpus uteri, which includes the body of the uterus. This code encompasses various types of uterine cancers that do not fit neatly into other specific categories. The corpus uteri is a common site for gynecologic malignancies, including endometrial carcinoma, which is the most prevalent type of uterine cancer. The diagnosis often involves a combination of imaging studies, histopathological examination, and tumor marker assessments, such as CA-125, which can aid in monitoring treatment response and disease progression. Staging of the malignancy is crucial for determining the appropriate treatment approach, which may include surgical intervention, radiation therapy, or chemotherapy. Surgical options often involve hysterectomy, which may be total or subtotal, depending on the extent of the disease. Accurate coding for C54.8 requires a thorough understanding of the clinical context and the specific characteristics of the neoplasm, as well as the documentation of any overlapping sites involved.
Detailed pathology reports, imaging studies, and surgical notes.
Diagnosis and treatment planning for uterine cancers, staging assessments, and follow-up care.
Ensure comprehensive documentation of tumor type, staging, and treatment response.
Imaging reports that detail findings related to the uterus and any associated structures.
Imaging for staging and monitoring of uterine malignancies.
Clear documentation of imaging findings that correlate with clinical diagnoses.
Performed for treatment of malignant neoplasm of the uterus.
Operative report detailing the procedure and findings.
Ensure alignment with oncological guidelines for surgical intervention.
CA-125 is a tumor marker that can be elevated in patients with malignant neoplasms of the uterus, including those coded as C54.8. It is often used to monitor treatment response and detect recurrence.
